Treatment of Alopecia Areata (AA) With Dupilumab in Patients With and Without Atopic Dermatitis (AD)
Trial · NCT03359356
Adverse events28
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 28
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Injection site reaction | Skin and subcutaneous tissue disorders | Placebo | 0 | 20 | 0 |
| other | Injection site reaction | Skin and subcutaneous tissue disorders | Dupilumab | 2 | 40 | 2 |
| other | Eosinophilic dermatitis | Skin and subcutaneous tissue disorders | Placebo | 0 | 20 | 0 |
| other | Eosinophilic dermatitis | Skin and subcutaneous tissue disorders | Dupilumab | 1 | 40 | 1 |
| other | Fall | General disorders | Placebo | 1 | 20 | 1 |
| other | Fall | General disorders | Dupilumab | 0 | 40 | 0 |
| other | Fatigue | General disorders | Placebo | 0 | 20 | 0 |
| other | Fatigue | General disorders | Dupilumab | 1 | 40 | 1 |
| other | Gastrointestinal symptoms | Gastrointestinal disorders | Placebo | 1 | 20 | 1 |
| other | Gastrointestinal symptoms | Gastrointestinal disorders | Dupilumab | 3 | 40 | 3 |
| other | Other orthopedic injuries/procedures | Musculoskeletal and connective tissue disorders | Placebo | 1 | 20 | 1 |
| other | Other orthopedic injuries/procedures | Musculoskeletal and connective tissue disorders | Dupilumab | 5 | 40 | 5 |
| other | Bladder malignancy | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | Placebo | 0 | 20 | 0 |
| other | Bladder malignancy | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | Dupilumab | 1 | 40 | 1 |
| other | Prostatic hyperplasia | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | Placebo | 0 | 20 | 0 |
| other | Prostatic hyperplasia | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | Dupilumab | 1 | 40 | 1 |
| other | Facial rash | Infections and infestations | Placebo | 0 | 20 | 0 |
| other | Facial rash | Infections and infestations | Dupilumab | 1 | 40 | 1 |
| other | Conjuctivitis | Skin and subcutaneous tissue disorders | Placebo | 0 | 20 | 0 |
| other | Conjuctivitis | Skin and subcutaneous tissue disorders | Dupilumab | 4 | 40 | 4 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03359356/events